1. Home
  2. UP vs LCTX Comparison

UP vs LCTX Comparison

Compare UP & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wheels Up Experience Inc.

UP

Wheels Up Experience Inc.

HOLD

Current Price

$0.52

Market Cap

476.3M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.54

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UP
LCTX
Founded
2013
1990
Country
United States
United States
Employees
1866
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
476.3M
407.7M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
UP
LCTX
Price
$0.52
$1.54
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.8M
1.1M
Earning Date
04-30-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
N/A
$55.75
Revenue Next Year
N/A
$2.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.24
52 Week Low
$0.49
$0.37
52 Week High
$3.50
$2.09

Technical Indicators

Market Signals
Indicator
UP
LCTX
Relative Strength Index (RSI) 41.12 42.02
Support Level $0.49 $1.55
Resistance Level $0.59 $1.84
Average True Range (ATR) 0.04 0.10
MACD 0.00 -0.03
Stochastic Oscillator 29.21 25.47

Price Performance

Historical Comparison
UP
LCTX

About UP Wheels Up Experience Inc.

Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: